Your session is about to expire
← Back to Search
Alkylating agents
Chemotherapy + Rituximab for Non-Hodgkin's Lymphoma
Phase 2
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age: 18 and over
Histologically confirmed intermediate or high grade non-Hodgkin's lymphoma Stage II, III, or IV disease B-cell where lymphoid cells are CD20 or CD19 positive
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is studying how well rituximab plus combination chemotherapy works in treating patients with non-Hodgkin's lymphoma.
Who is the study for?
This trial is for adults with intermediate or high-grade non-Hodgkin's lymphoma, stages II-IV, who haven't been treated before. Participants must have B-cell lymphoid cells that are CD20 or CD19 positive and no brain metastases. They should be relatively healthy otherwise, not pregnant or nursing, and using effective contraception.Check my eligibility
What is being tested?
The study is testing the combination of rituximab (a monoclonal antibody) with various chemotherapy drugs to see if they work better together in treating non-Hodgkin's lymphoma compared to standard treatments. It's a Phase II trial focused on effectiveness.See study design
What are the potential side effects?
Rituximab can cause infusion reactions like fever and chills; body aches; fatigue; skin rashes; and potential serious complications including infections. Chemotherapy may lead to nausea, hair loss, mouth sores, low blood cell counts increasing infection risk.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
My lymphoma is intermediate or high grade, stage II-IV, and my cells are CD20 or CD19 positive.
Select...
My heart is healthy with no severe diseases or failure.
Select...
My cancer can be measured or seen on tests.
Select...
My creatinine level is 2.0 mg/dL or lower.
Select...
My liver tests are within the required limits.
Select...
I do not have any current infections.
Select...
I can care for myself but may not be able to do active work.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
AmgenLead Sponsor
1,370 Previous Clinical Trials
1,377,688 Total Patients Enrolled
59 Trials studying Lymphoma
6,899 Patients Enrolled for Lymphoma
Carol Brannan, BS, BSNStudy ChairAmgen
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I am not on any biological treatments except for epoetin alfa.My lymphoma is intermediate or high grade, stage II-IV, and my cells are CD20 or CD19 positive.My heart is healthy with no severe diseases or failure.My cancer has not spread to my brain.My cancer can be measured or seen on tests.I have not received any treatment for lymphoma.I have no history of serious heart conditions.My creatinine level is 2.0 mg/dL or lower.My lymphoma is not classified as mantle cell, lymphoblastic, or peripheral T-cell.I am not taking antibiotics to prevent infections.My liver tests are within the required limits.I do not have any current infections.I have not received any white blood cell transfusions.I am not currently receiving chemotherapy.I can care for myself but may not be able to do active work.I am not currently undergoing radiotherapy.It has been more than 2 weeks since my last major surgery.I haven't had any cancer in the past 5 years, except for certain skin cancers or cervical pre-cancer.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has this therapeutic intervention been accepted by the FDA?
"As this is a Phase 2 trial, our scientific team at Power judged the safety of the treatment to be moderate and assigned it a score of 2. Although there are indications that it may prove safe, no data has yet been collected regarding efficacy."
Answered by AI
How many healthcare facilities are participating in the experiment?
"Currently, this research study is recruiting participants from 27 different sites around the country. Some of these locations include Rancho Mirage, Pensacola and Cincinnati. To reduce travel time for potential enrollees it would be beneficial to choose a clinical trial centre closest to you."
Answered by AI
Is recruitment still open for this clinical experiment?
"Reports on clinicaltrials.gov indicate that this medical investigation is not currently enrolling participants; the trial was first advertised in December of 1999 and its details were last updated more than six years ago, but there are 1750 other studies actively taking patients at present."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger